A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Lipodystrophy

Interventions

DRUG: mibavademab

Sponsor

Regeneron Pharmaceuticals